Abstract
Crosstalk between G protein-coupled receptors (GPCRs) is one of the key mechanisms used by the cell for integrating multiple signaling pathways. Functional crosstalk at the level of signaling pathways was initially thought to regulate receptor function. Importantly, the existence of GPCR heteromers demonstrates that direct physical interactions between GPCRs could also be behind the crosstalk phenomenon. Neurological disorders such as Parkinsons disease (PD) and schizophrenia have been linked to a dysfunctional communication between certain GPCRs. In this review, we discuss functional and physical crosstalk of the main GPCR families involved in the aforementioned disorders. In addition, we analyze the available structural information on physical crosstalk and highlight some strategies in drug discovery based on these crosstalk mechanisms.
Keywords: Dimerisation, drug discovery, GPCR, heteromers, receptor crosstalk, receptor signaling, Parkinson disease, schizophrenia, Neurological disorders, crosstalk mechanisms
Current Medicinal Chemistry
Title: Crosstalk within GPCR Heteromers in Schizophrenia and Parkinsons Disease: Physical or Just Functional?
Volume: 19 Issue: 8
Author(s): R. Guixa-Gonzalez, A. Bruno, M. Marti-Solano and J. Selent
Affiliation:
Keywords: Dimerisation, drug discovery, GPCR, heteromers, receptor crosstalk, receptor signaling, Parkinson disease, schizophrenia, Neurological disorders, crosstalk mechanisms
Abstract: Crosstalk between G protein-coupled receptors (GPCRs) is one of the key mechanisms used by the cell for integrating multiple signaling pathways. Functional crosstalk at the level of signaling pathways was initially thought to regulate receptor function. Importantly, the existence of GPCR heteromers demonstrates that direct physical interactions between GPCRs could also be behind the crosstalk phenomenon. Neurological disorders such as Parkinsons disease (PD) and schizophrenia have been linked to a dysfunctional communication between certain GPCRs. In this review, we discuss functional and physical crosstalk of the main GPCR families involved in the aforementioned disorders. In addition, we analyze the available structural information on physical crosstalk and highlight some strategies in drug discovery based on these crosstalk mechanisms.
Export Options
About this article
Cite this article as:
Guixa-Gonzalez R., Bruno A., Marti-Solano M. and Selent J., Crosstalk within GPCR Heteromers in Schizophrenia and Parkinsons Disease: Physical or Just Functional?, Current Medicinal Chemistry 2012; 19 (8) . https://dx.doi.org/10.2174/092986712799320574
DOI https://dx.doi.org/10.2174/092986712799320574 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: The Role of Ca2+-activated K+ Channels of Intermediate Conductance in Glioblastoma Malignancy
Current Neuropharmacology New Cathepsin D Inhibitorswith Hydroxyethylamine Isosteres: Preparation and Characterization
Medicinal Chemistry Identification of Nuclear Proteins in Soybean Under Flooding Stress using Proteomic Technique
Protein & Peptide Letters Mitochondria Play a Central Role in Estrogen-Induced Neuroprotection
Current Drug Targets - CNS & Neurological Disorders The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Maternal Exposure to Quetiapine: Effects on Structural Changes in Developing Brain and its Lasting Impact on Neurobehavioral Impairments in Rat Offspring
Current Psychopharmacology Melanocortins in the Treatment of Male and Female Sexual Dysfunction
Current Topics in Medicinal Chemistry Towards Next Generation Adenosine A<sub>2A</sub> Receptor Antagonists
Current Medicinal Chemistry Expression Analysis of 4-Hydroxynonenal Modified Proteins in Schizophrenia Brain; Relevance to Involvement in Redox Dysregulation
Current Proteomics Patient Education and Telemedicine in COPD - Update 2015
Current Respiratory Medicine Reviews Target-directed Discovery and Bioprocess Engineering of New Enzymes for Environmentally Benign Production of High-Value Chiral Chemicals
Current Organic Chemistry Formation of Five- and Six-Membered α,β-Unsaturated Lactones through Ring- Closing Metathesis of Functionalized Acrylates. Applications to Synthesis of Natural Products
Current Organic Chemistry Modulation of Endoplasmic Reticulum Stress: An Opportunity to Prevent Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction
Current Pharmaceutical Design Novel Piperazinyl Derivatives with Anti-Hyperalgesic, Anti-Allodynic and Anti-Inflammatory activities Useful for the Treatment of Neuropathic Pain
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis, Molecular Docking and Anticancer Evaluation of New Arylazothiazoles
Current Organic Synthesis Methods for Detection of Speech Impairment Using Mobile Devices
Recent Patents on Signal Processing (Discontinued) Radix Angelica Sinensis that Contains the Component Z-Ligustilide Promotes Adult Neurogenesis to Mediate Recovery from Cognitive Impairment
Current Neurovascular Research Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets